用单药组合治疗高血压:一种简单的策略,可以为患者和支付人节省成本
Miriam Pikkemaat1,2, Emily R Atkins3, Anthony Rodgers3
1Center for Primary Healthcare Research, Department of Clinical Sciences, Malmö, Lund University, Malmö.
Journal of hypertension
|June 18, 2025
概括
治疗高血压的单片药组合 (SPC) 始终为患者和政府节省资金. 这些成本节省,主要来自降低的处方费用,使SPC成为经济上有利的选择,而不是免费药物组合.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 心血管疾病管理管理
背景情况:
- 高血压管理通常涉及多种药物.
- 单片药物组合 (SPC) 为免费药物组合提供了一个方便的替代方案.
- 了解对患者和医疗保健系统的成本影响至关重要.
研究的目的:
- 为了比较单片药物组合 (SPC) 与用于高血压治疗的免费药物组合的直接成本.
- 从患者和政府的角度分析成本.
- 在不同的澳大利亚制药福利计划 (PBS) 安全网门下评估成本效益.
主要方法:
- 在澳大利亚进行了成本分析.
- 审查了来自澳大利亚PBS物品药物地图的数据.
- 计算了总成本,包括药品成本和药房费用.
- 分析考虑了患者和政府支出,包括安全网值.
主要成果:
- 对患者来说,SPC总是比免费药物组合更便宜,一般患者在到达安全网之前平均节省了30%.
- 对于政府来说,SPC通常成本更低,特别是对于特许卡持有者 (11-26%的节省) 和安全网后的一般患者 (11%的节省).
- 在到达安全网之前,政府在一般患者中观察到较小的成本增加 (16%),这是由于开药费的节省,即使有60天的开药政策.
结论:
- 与高血压管理中的免费药物组合相比,单片药物组合 (SPC) 对患者和政府都有显著的成本节省.
- 这些经济效益应在新兴和现有高血压治疗的处方决策中考虑.
- 节省的主要驱动力是降低分发费用,突出了固定剂量组合的经济优势.
相关概念视频
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
56
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
56
01:23Hypertension V: Nursing Management
50
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
50
01:25Antihypertensive Drugs: Direct Renin Inhibitors
849
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
849
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
263
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
263